How the heart drug levosimendan works in adults
Part of Heart & circulation clinical trials.
This study looks at how the drug levosimendan, which helps the heart pump better during shock, works in the body of adults in the ICU. By measuring drug levels in the blood, researchers hope to find the best dosing for each person.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Weigh at least 50 kilograms (about 110 pounds)
- Be admitted to an intensive care unit
- Have cardiogenic shock (a serious condition where the heart can't pump enough blood)
- Be scheduled to receive a medication called levosimendan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving levosimendan early (a heart-strengthening medicine) improves outcomes compared with placebo, on top of standard inotropic support, in people with cardiogenic shock. It mainly looks at whether patients have fewer serious complications or deaths.
This trial tests if unloading the heart during ECMO support helps patients recover better from cardiogenic shock. It compares different ways to reduce the heart's workload.
This study tests a device that helps the heart pump blood when it is too weak to do so, even with medicine, after surgery, or while waiting for a transplant. It aims to see if it's safe and works well.
This early study looks at how well the heart is pumping in people with cardiogenic shock, using measurements taken during a right-heart catheter (a small pressure-monitoring test). It may help doctors better assess heart function and guide next-step treatments like LVAD, heart transplant, or valve surgery.
This study tracks how well people with cardiogenic shock (a life-threatening drop in blood flow after a heart attack or heart failure worsening) do when treated with modern support devices and medicines.
This study tests a special monitoring approach (likely using an implanted device) to help prevent serious complications after you survive cardiogenic shock in the hospital. It may help the care team detect problems earlier so treatments can start sooner.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.